<DOC>
	<DOCNO>NCT00713284</DOCNO>
	<brief_summary>The purpose study determine whether combination Myfortic sirolimus effective prevent rejection preserve kidney function stable kidney transplant recipient .</brief_summary>
	<brief_title>Study Evaluating Conversion From Tacrolimus Sirolimus Stable Kidney Transplant Recipients Receiving Myfortic</brief_title>
	<detailed_description>One-year graft survival renal transplantation dramatically improve addition calcineurin inhibitor ( tacrolimus cyclosporine ) maintenance immunosuppression regimens . Much improvement early graft survival attribute efficacy calcineurin inhibitor prevent early acute rejection episode . However , long-term graft survival improve great magnitude improvement short-term survival . In addition , research show progressive decline kidney function throughout year post-transplantation . Clinical research focus improve long term graft survival maintain long-term kidney function . The lead cause graft loss attribute chronic allograft nephropathy ( CAN ) . Risk factor CAN include : prolonged ischemia time , delay graft function , acute rejection episode calcineurin inhibitor nephrotoxicity ( CIN ) . CIN identify common identifiable contributor CAN chief cause late histologic injury ongoing decline renal function . At 10 year post-transplant , CIN find universally prevalent . Calcineurin inhibitor minimization elimination study seek improve long-term allograft function minimize exposure nephrotoxic agent . Studies demonstrate early withdrawal cyclosporine cyclosporine , sirolimus steroid immunosuppression regimen 3 month post-transplant improved renal function graft survival 48 month post-transplant . Other study demonstrate diminished prevalence CAN 2 year post-transplant patient maintain sirolimus compare cyclosporine . Kidney function also significantly improve low serum creatinine high GFR sirolimus maintenance group . Sirolimus macrolide antibiotic immunosuppressive agent exerts mechanism action inhibit mTOR signal cascade . In clinical trial , sirolimus find lack nephrotoxic effect compare cyclosporine . In kidney transplantation , multiple study demonstrate safety efficacy sirolimus calcineurin inhibitor avoidance withdrawal protocol . Myfortic® ( mycophenolate acid ) enteric coat formulation mycophenolic acid ( MPA ) approve prevention rejection kidney transplant recipient combination cyclosporine corticosteroid . Myfortic® document nephrotoxic effect . Mycophenolate mofetil ( MMF ) , prodrug MPA also demonstrate nephrotoxic effect . Early study demonstrate therapeutic equivalence Myfortic® MMF de novo renal transplant conversion study MMF convert Myfortic least 6 month renal transplantation . Thus , study demonstrate safety efficacy MMF sirolimus calcineurin inhibitor withdrawal protocol also hold true use Myfortic® regimen . This study ass safety efficacy Myfortic® use simultaneous sirolimus conversion calcineurin inhibitor withdrawal regimen stable renal transplant recipient . Study subject receive immunosuppression consist Myfortic® , tacrolimus corticosteroid ( prednisone ) start day transplant . Conversion tacrolimus ( Prograf ) sirolimus ( Rapamune ) occur 90 180 day post cadaver-donor living-donor renal transplant . All participant convert tacrolimus sirolimus remain Myfortic® current corticosteroid taper .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria I ( 1 7 day post renal allograft transplant ) : Male female patient 18 year age old . Patient fully inform study procedure requirement , sign IRB approve consent form willing able follow study procedure . Exclusion Criteria I ( 1 7 day post renal allograft transplant ) : Patient previously receive organ transplant . Patient identify donor specific antibody prior transplant Patient know seropositive human immunodeficiency virus ( HIV ) . Patient active Hepatitis C B infection document positive DNA PCR . Patients seropositive Hepatitis C virus ( HCV ) B virus ( HBV ) negative HCVRNA HBVDNA PCR may include . Patient current malignancy history malignancy within past 5 year , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Patient uncontrolled infection unstable medical condition could interfere study objective . Patient currently take take investigational drug past 30 day . Patient known hypersensitivity sirolimus Myfortic® . Patient pregnant lactating . Patient unlikely comply visit schedule protocol . Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator . Inclusion Criteria II ( 90 180 day post renal allograft transplant ) : Patient 90 180 day receive primary living cadaverdonor renal allograft Patient maintain regimen tacrolimus , Myfortic® corticosteroids prior study enrollment . Patient stable allograft define calculated GFR &gt; 30 mL/min use Nankivell equation . Patient fully inform study procedure requirement , sign IRB approve consent form willing able follow study requirement . Female patient child bear potential must use least one reliable form contraception unless status post bilateral tubal ligation , bilateral oophorectomy hysterectomy . Effective contraception must use duration study . Exclusion Criteria II ( 90 180 day post renal allograft transplant ) : Patient experience acute graft rejection ≥ Banff '97 1b humoral rejection determine biopsy within first 90 day posttransplant Patient experience acute graft rejection ≤ Banff 97 1a determine biopsy within 30 day prior Baseline visit . Patient untreated hypercholesterolemia define triglyceride &gt; 300 total cholesterol &gt; 200 within previous 30 day . Patient currently ( &lt; 7 day ) leukopenic define WBC &lt; 3,000 cells/mL thrombocytopenic define platelet &lt; 100,000 cells/mL . Patient significant liver disease , define past 30 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>